Cosmetic GMP for “Cosmeceutical” Products: An  Quality and Compliance Playbook

Cosmetic GMP for Cosmeceuticals: ISO 22716, FDA and ASEAN  Guide

A practical English guide to cosmetic GMP for skincare and cosmeceutical products: classification, claims, water, microbiology, batch records, stability, CAPA and recalls.

Introduction

A “cosmeceutical” is not a single legal product category. It is a commercial term often used for cosmetics positioned around active ingredients or science-based benefits. Before building a GMP system, the company must determine whether the product is a cosmetic, a cosmetic carrying drug claims, an OTC drug, or another regulated product in each target market.

The U.S. FDA explains that classification depends largely on intended use. Intended use may be established through labeling, advertising, websites, consumer perception and the known use of ingredients. A product can be a cosmetic, a drug, or both. Claims to treat disease, kill microorganisms, restore hair growth, relieve pain, or affect the structure or function of the body may move a product into drug territory.

This article focuses on cosmetic and cosmetic-like manufacturing controls. It does not cover food cGMP and does not treat pharmaceutical drug GMP as the default framework for every skincare product.

A — Applicable category, claims and market scope

Cosmetic is not a universal legal category with identical rules

The same sunscreen, anti-dandruff shampoo, acne product or antibacterial cleanser may be regulated differently across markets. A company should create a market-by-market classification memo covering intended use, claims, active ingredients, route of application, use around the eyes or mucous membranes, and whether the product is absorbed, injected or intended for internal use.

Do not rely on the word “cosmeceutical.” FDA does not recognize it as a legal category.  Claims must be reviewed not only on the label but also in digital advertising, influencer scripts, product pages and sales training.

GMP references are systems, not one universal certificate

ISO 22716:2007 provides guidelines for the production, control, storage and shipment of cosmetic products. ISO states that the standard addresses product quality aspects but does not cover occupational safety, environmental protection, R&D or distribution of finished products.

FDA has cosmetic GMP guidance and inspection-oriented recommendations. ASEAN has Cosmetic GMP Guidelines intended to support the ASEAN cosmetic regulatory framework. A third-party ISO certificate, a facility license, product notification or registration is not the same thing as a universal “cGMP certificate.” The company remains responsible for product safety, quality and truthful claims.

B — Quality management and governance

A practical system includes a quality policy, organization chart, documented responsibilities, change governance, risk management, document control and management review. The Quality Unit should be able to place materials or batches on hold, require investigations and reject inadequate evidence.

Quality objectives should be measurable. Useful indicators include right-first-time batch documentation, deviation recurrence, OOS rate, microbial alert rate, CAPA effectiveness, complaint rate and mock-recall performance.

C — Competent personnel and hygiene

Personnel should have education, training and experience appropriate to their assigned functions. People handling raw materials, bulk product, finished product or product-contact surfaces should use suitable clean clothing and protective apparel and maintain personal cleanliness. FDA cosmetic GMP guidance also recommends controlling food, drink, tobacco and unauthorized access in manufacturing and storage areas.

Training should be task-based. A weighing operator must identify material, lot and status. A compounding operator must understand order of addition, temperature, mixing and hold limits. A filling operator must perform line clearance and fill checks. A reviewer must understand raw data, corrections and escalation.

D — Premises, zoning and equipment

The facility should support orderly movement of people, materials, waste and product. Receiving, sampling, quarantine, released stock, rejected stock, weighing, compounding, bulk holding, filling, packing and retained samples should have clear status controls.

Equipment should be suitable in design, size, material and accuracy. Product-contact surfaces should be cleanable and maintained. Balances, meters, tanks, pumps, pipes and filling heads need identification, calibration or checks, maintenance and cleaning records.

E — Water, utilities and microbiological control

Water is often a major ingredient in lotions, gels, shampoos and emulsions. FDA recommends defining the quality of water used as a cosmetic ingredient, monitoring chemical, physical and microbiological attributes, controlling treatment-system materials, preventing stagnation and sanitizing the supply system to prevent biofilm.

A sound water program includes a system diagram, sample points, specifications, alert/action limits, sampling frequency, sanitation procedure, trend review and deviation response. Reverse osmosis, deionization or UV equipment does not by itself prove that the water is suitable.

Microbiological control should match formulation and use. Controls may include raw-material testing, water testing, environmental hygiene, finished-product microbial testing, preservative strategy and, where appropriate, a preservative efficacy or challenge study. Limits must be scientifically and regulatorily justified for the product and market.

F — Materials, packaging and supplier control

Raw materials should be identified, stored under suitable conditions, sampled or otherwise assessed, and released before use. Labels should show identity, lot and status. Materials must be protected from mix-ups, contamination, degradation, heat, light and moisture.

Supplier qualification should consider source, specifications, testing capability, change notification, transport, microbial risk and history. A certificate of analysis is evidence, not a transfer of the manufacturer’s responsibility.

Packaging deserves the same discipline. Containers, closures, pumps, tubes, jars and labels should be assessed for compatibility, closure integrity, protection from light/oxygen/moisture, functionality and mix-up risk.

G — Formula, dispensing, compounding and filling

The master formula should define ingredients, quantities, tolerances, order of addition, equipment, process parameters, in-process controls and theoretical yield. Dispensing requires line clearance, verified identity, lot number, scale status and independent checks where appropriate.

Compounding controls may include temperature, mixing speed, time, vacuum, pH, viscosity, hydration, emulsion formation, color dispersion, deaeration and bulk hold time. The critical parameters should be determined by product and process risk rather than copied from another formula.

Filling and packing should control line clearance, correct components, fill weight or volume, code and batch number, seal integrity, reconciliation and finished-product status. Bulk product awaiting filling should have defined identification, storage and hold-time limits.

H — Records and data integrity

A batch record should reconstruct what happened: who performed each operation, when, with which materials and equipment, under what conditions, with what result and how exceptions were handled. Entries should be contemporaneous, legible, attributable and protected from undocumented overwriting.

Electronic systems should use individual accounts, role-based access, audit trails, backup, retention, time controls and change management. A failed run, unexpected peak or unfavorable microbial result must not disappear because a later result passed.

I — Laboratory control and stability

Laboratory controls should cover incoming materials, water, bulk and finished products with methods appropriate to the purpose. Depending on the product, tests may include identity, appearance, pH, viscosity, density, assay or marker, microbial quality, fill weight/volume, uniformity, packaging function and preservative performance.

Stability should address the actual formula and package. Trend review may include appearance, odor, color, pH, viscosity, microbial quality, marker content, closure integrity and dispensing performance. Changes in formula, supplier, package, manufacturing scale or claims may require additional stability work.

J — Qualification, validation and verification

The depth of qualification and validation should be risk-based. Relevant activities may include utility and equipment qualification, cleaning validation or verification, hold-time studies, process validation, analytical method suitability, computerized-system validation and transport verification.

Validation is not a document-signing exercise. Acceptance criteria should connect to product quality and process capability. Continued verification uses deviations, complaints, stability and trends to confirm that the process remains in control.

K — Deviations, OOS, CAPA, change control and audits

A deviation record should capture the event, immediate containment, batch impact, root-cause work, disposition and follow-up. An OOS investigation should preserve original data and assess laboratory, sample, instrument, method, material, water and process factors. Repeated testing until a passing result appears is not a defensible investigation.

Change control should cover formula, preservative, supplier, package, equipment, water, software, method, label and claims. The assessment should address validation, stability, training, product information, market commitments and traceability.

Internal audits should test whether controls work. Can the site retrieve raw data? Can it identify all batches using a material? Can it show that a CAPA worked? Can it explain a trend without reconstructing records?

L — Complaints, adverse events, recalls and traceability

Complaint handling should capture product and lot numbers, photographs, storage and use conditions, symptoms, medical treatment, samples and distribution information. Complaints should be trended with deviations, microbial results, stability and returns.

Under the U.S. Modernization of Cosmetics Regulation Act of 2022, a responsible person must report serious adverse events associated with cosmetic products to FDA within 15 business days, subject to the applicable statutory requirements. MoCRA also introduced facility registration, product listing, records access and mandatory-recall authorities in specified circumstances.

Traceability should connect raw material, packaging, batch, finished units, customers, markets and complaints. A mock recall should measure retrieval speed, reconciliation and effectiveness, not merely produce a signed form.

 Implementation workflow

  1. Define intended use, claims, route, market and legal category.
  2. Build the product quality profile and risk assessment.
  3. Select the applicable cosmetic GMP references and legal obligations.
  4. Establish an empowered Quality Unit and responsibility matrix.
  5. Define premises, utilities, equipment, cleaning and data requirements.
  6. Qualify suppliers and approve material and packaging specifications.
  7. Approve the formula, master batch record, SOPs and methods.
  8. Qualify or validate equipment, utilities, processes and relevant systems.
  9. Train personnel and execute controlled pilot or validation batches.
  10. Manufacture, fill, pack, test and document contemporaneously.
  11. Review batch records, raw data, stability, deviations and complaints.
  12. Release, distribute, audit, trend and maintain continued process control.

Scenario

A moisturizer’s microbial result is within specification but has increased steadily across three stability pulls. The site should not close the matter because the result is technically passing. It should review water trends, cleaning records, bulk hold time, preservative system, raw materials, package use pattern and sample handling. The outcome may be a preventive CAPA, additional monitoring, a stability extension, a formula change or market action, depending on the evidence.

FAQ

Is “cosmeceutical GMP” an official global certification? No. It is not a universal legal category. The applicable system depends on product classification, claims and market.

Does ISO 22716 replace local cosmetic law? No. It is a GMP guideline. Local notification, safety, labeling, claims, facility and post-market obligations remain separate.

When can a cosmetic become an OTC drug? When intended use, claims, ingredients or presentation meet the drug definition or OTC conditions in the target market. The answer must be assessed market by market.

Is a final pass result enough for release? No. Release should consider materials, process records, filling, packaging, laboratory raw data, deviations, stability and complaints where relevant.

Does FDA “certify” a cosmetic factory as cGMP? Registration or inspection status is not the same as a single FDA-issued universal cGMP certificate. A company must maintain the controls and evidence required by applicable law.

References

: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap “FDA: Is It a Cosmetic, a Drug, or Both?”

: https://www.iso.org/standard/36437.html “ISO 22716:2007 — Cosmetics Good Manufacturing Practices”

: https://www.fda.gov/media/86366/download “FDA Guidance for Industry: Cosmetic Good Manufacturing Practice Guidelines/Inspection Checklist”

: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra “FDA: Modernization of Cosmetics Regulation Act of 2022”

: https://www.aseancosmetics.org/docdocs/AppendixVI.pdf “ASEAN Guidelines for Cosmetic Good Manufacturing Practices”

Contact us for cGMP Standard consulting services in Vietnam

ISC Global

Hotline/Zalo: +84 933 096 426 – +84 868 591 260

Email: info@iscglobal.asia | van.pham@iscglobal.asia

Website: iscglobal.asia | iscglobal.edu.vn

SA8000:2026 Certification Guide: Principles, Management Criteria and the 2026–2029 Transition

SA8000:2026 certification guide SA8000:2026 transition, SA8000 certification process, SA8000 CAB SAAS, decent work standard A practical English guide to[…]

ISO 13485:2016 for Global Medical Device Organizations

ISO 13485:2016 Explained: QMS, Risk, Compliance and Certification A practical English guide to ISO 13485:2016 covering QMS, regulatory requirements,[…]

Cosmetic GMP for “Cosmeceutical” Products: An  Quality and Compliance Playbook

Cosmetic GMP for Cosmeceuticals: ISO 22716, FDA and ASEAN  Guide A practical English guide to cosmetic GMP for skincare[…]

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *